Literature DB >> 25987065

Aberrant Expression of HOXA5 and HOXA9 in AML.

Peng Zhao1, Li Tan, Jian Ruan, Xiao-Ping Wei, Yi Zheng, Li-Xia Zheng, Wei-Qin Jiang, Wei-Jia Fang.   

Abstract

BACKGROUND: Aberrant expression of HOX gene expression has been observed in cancer. The purpose of this study was to investigate the alteration of HOXA5 and HOXA9 expression and their clinical significance in acute meloid leukemia (AML).
MATERIALS AND METHODS: The expression of HOXA5 and HOXA9 genes of bone marrow samples from 75 newly diagnosed AML patients and 22 healthy controls for comparison were examined by Real- time quantitative PCR (RQ-PCR) assay. Statistical analysis was conducted to evaluate HOXA5 and HOXA9 expression as possible biomarkers for AML.
RESULTS: The results showed that the complete remission rate (52.6%) of the patients who highly expressed HOXA5 and HOXA9 was significantly lower than that (88.9%) in patients who lowly express the genes (P=0.015). Spearmann correlation coefficients indicated that the expression levels for HOXA5 and HOXA9 genes were highly interrelated (r=0.657, P<0.001). Meanwhile, we detected significant correlations between HOXA9 expression and age in this limited set of patients (P=0.009).
CONCLUSIONS: The results suggest a prognostic impact of increased expression of HOXA5 and HOXA9 in AML patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25987065     DOI: 10.7314/apjcp.2015.16.9.3941

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  5 in total

1.  Higher expression levels of the HOXA9 gene, closely associated with MLL-PTD and EZH2 mutations, predict inferior outcome in acute myeloid leukemia.

Authors:  Li Gao; Junzhong Sun; Fang Liu; Hui Zhang; Yigai Ma
Journal:  Onco Targets Ther       Date:  2016-02-09       Impact factor: 4.147

2.  EGR1 mediates miR-203a suppress the hepatocellular carcinoma cells progression by targeting HOXD3 through EGFR signaling pathway.

Authors:  Lumin Wang; Hongfei Sun; Xiaofei Wang; Ni Hou; Lingyu Zhao; Dongdong Tong; Kang He; Yang Yang; Tusheng Song; Jun Yang; Chen Huang
Journal:  Oncotarget       Date:  2016-07-19

3.  Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.

Authors:  Yunan Li; Mingying Zhang; Mengyao Sheng; Peng Zhang; Zizhen Chen; Wen Xing; Jie Bai; Tao Cheng; Feng-Chun Yang; Yuan Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2018-03-28       Impact factor: 4.553

Review 4.  Molecular implications of HOX genes targeting multiple signaling pathways in cancer.

Authors:  U Sangeetha Shenoy; Divya Adiga; Shama Prasada Kabekkodu; Keith D Hunter; Raghu Radhakrishnan
Journal:  Cell Biol Toxicol       Date:  2021-10-06       Impact factor: 6.691

5.  Silencing of HMGA2 reverses retardance of cell differentiation in human myeloid leukaemia.

Authors:  Li Tan; Hongfa Xu; Guoshu Chen; Xiaoping Wei; Baodan Yu; Jingmei Ye; Lihua Xu; Huo Tan
Journal:  Br J Cancer       Date:  2018-01-02       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.